References
- Vlahovic TC. Onychomycosis: evaluation, treatment options, managing recurrence, and patient outcomes. Clin Podiatr Med Surg. 2016 Jul;33(3):305–318. doi: 10.1016/j.cpm.2016.02.001
- Gupta AK, Stec N, Summerbell RC, et al. Onychomycosis: a review. J Eur Acad Dermatol Venereol. 2020 Sep;34(9):1972–1990. doi: 10.1111/jdv.16394
- Roberts DT. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol. 1992 Feb;126(Suppl 39):23–27. doi: 10.1111/j.1365-2133.1992.tb00005.x
- Vasconcellos C, Pereira CQ, Souza MC, et al. Identification of fungi species in the onychomycosis of institutionalized elderly. An Bras Dermatol. 2013 May;88(3):377–380. doi: 10.1590/abd1806-4841.20131884
- Gupta AK, Jain HC, Lynde CW, et al. Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists’ offices in Ontario, Canada – a multicenter survey of 2001 patients. Int J Dermatol. 1997;36(10):783–787.
- Gupta AK, Jain HC, Lynde CW, et al. Prevalence and epidemiology of onychomycosis in patients visiting physicians’ offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol. 2000;43(2):244–248.
- Del Rosso JQ. The role of topical antifungal therapy for onychomycosis and the emergence of newer agents. J Clin Aesthet Dermatol. 2014;7(7):10.
- Falotico JM, Lipner SR. Updated perspectives on the diagnosis and management of Onychomycosis. Clin Cosmet Investig Dermatol. 2022;Volume 15:1933–1957. doi: 10.2147/CCID.S362635
- Gupta AK, Einarson TR, Summerbell RC, et al. An overview of topical antifungal therapy in dermatomycoses. Drugs. 1998;55(5):645–674.
- Lipner SR, Joseph WS, Vlahovic TC, et al. Therapeutic recommendations for the treatment of Toenail onychomycosis in the US. J Drugs Dermatol. 2021 Oct 1;20(10):1076–1084. doi: 10.36849/JDD.6291
- Poulin Y, Thomas R, Gupta AK. Brief treatment guide for onychomycosis. J Cutan Med Surg. 2006;10(6_suppl):S39–S43. doi: 10.2310/7750.2006.00055
- Gupta AK, Foley KA. Antifungal treatment for pityriasis versicolor. Journal Of Fungi. 2015;1(1):13–29. doi: 10.3390/jof1010013
- Nofal A, Fawzy MM, El-Hawary EE. Successful treatment of resistant onychomycosis with voriconazole in a liver transplant patient. Dermatol Ther. 2020 Nov;33(6):e14014. doi: 10.1111/dth.14014
- Krishna G, Ma L, Martinho M, et al. Determination of posaconazole levels in toenails of adults with onychomycosis following oral treatment with four regimens of posaconazole for 12 or 24 weeks. Antimicrob Agents Chemother. 2011 Sep;55(9):4424–4426. doi: 10.1128/AAC.01302-10
- Galimberti R, Negroni R, Iglesia de Elias Costa M, et al. The activity of ketoconazole in the treatment of onychomycosis. Rev Infect Dis. 1980;2(4):596–598.
- Chen M, Suzuki A, Thakkar S, et al. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today. 2016 Apr;21(4):648–653. doi: 10.1016/j.drudis.2016.02.015
- García Rodríguez LA, Duque A, Castellsague J, et al. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol. 1999 Dec;48(6):847–852. doi: 10.1046/j.1365-2125.1999.00095.x
- Waters K FDA drug safety podcast: FDA warns that prescribing of nizoral (ketoconazole) oral tablets for unapproved uses including skin and nail infections continues; linked to patient death 2022 [cited 2023 Aug 14]. Available from: www.fda.gov/drugs/fda-drug-safety-podcasts/fda-drug-safety-podcast-fda-warns-prescribing-nizoral-ketoconazole-oral-tablets-unapproved-uses
- Griseofulvin 125 mg Tablets (MHRA, UK) 2021 [cited 2023 Aug 14]. Available from: www.medicines.org.uk/emc/product/12894/smpc/print
- Terbinafine (Lamisil) 250 mg Tablet Package Insert (FDA, USA) 2019 [cited 2023 Aug 14]. Available from: www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020539
- Gupta AK, Katz HI, Shear NH. Drug interactions with itraconazole, fluconazole, and terbinafine and their management. J Am Acad Dermatol. 1999 Aug;41(2 Pt 1):237–249. doi: 10.1016/S0190-9622(99)70055-1
- Lo AC, Lui SL, Lo WK, et al. The interaction of terbinafine and cyclosporine a in renal transplant patients. Br J Clin Pharmacol. 1997 Mar;43(3):340–341.
- van der Kuy PH, Hooymans PM, Kuy P-HMVD, et al. Nortriptyline intoxication induced by terbinafine. BMJ. 1998 Feb 7;316(7129):441. doi: 10.1136/bmj.316.7129.441
- Tassaneeyakul W, Birkett DJ, McManus ME, et al. Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. Biochem Pharmacol. 1994;47(10):1767–1776.
- Trépanier EF, Nafziger AN, Amsden GW. Effect of terbinafine on theophylline pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother. 1998 Mar;42(3):695–697. doi: 10.1128/AAC.42.3.695
- Warwick JA, Corrall RJ. Drug points: serious interaction between warfarin and oral terbinafine. BMJ. 1998 Feb 7;316(7129):440. doi: 10.1136/bmj.316.7129.440
- Gupta AK, Ross GS. Interaction between terbinafine and warfarin. Dermatology. 1998;196(2):266–267. doi: 10.1159/000017890
- Itraconazole (Sporanox) 100 mg Capsules Package Insert (FDA, USA) 2022 [cited 2023 Aug 14]. Available from: www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020083
- Lempers VJ, van den Heuvel JJ, Russel FG, et al. Inhibitory potential of antifungal drugs on ATP-Binding cassette transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEP. Antimicrob Agents Chemother. 2016 Jun;60(6):3372–3379. doi: 10.1128/AAC.02931-15
- Wacher VJ, Silverman JA, Zhang Y, et al. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci. 1998 Nov;87(11):1322–1330. doi: 10.1021/js980082d
- Ondieki G, Nyagblordzro M, Kikete S, et al. Cytochrome P450 and P-Glycoprotein-Mediated interactions Involving African herbs indicated for common noncommunicable diseases. Evid Based Complement Alternat Med. 2017;2017:2582463. doi: 10.1155/2017/2582463
- Hunter J, Hirst BH. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. Adv Drug Delivery Rev. 1997;25(2–3):129–157. doi: 10.1016/S0169-409X(97)00497-3
- Ducharme MP, Slaughter RL, Warbasse LH, et al. Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. Clin Pharmacol Ther. 1995 Dec;58(6):617–624. doi: 10.1016/0009-9236(95)90017-9
- Drayton J, Dickinson G, Rinaldi MG. Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole. Clin Infect Dis. 1994 Feb;18(2):266. doi: 10.1093/clinids/18.2.266
- Fluconazole (Diflucan) 50-200 mg Tablets Package Insert (FDA, USA) 2023 [cited 2023 Aug 14]. Available from: www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019949
- Song JC, Deresinski S. Hepatotoxicity of antifungal agents. Curr Opin Invest Drugs. 2005;6(2):170–177.
- Gadour E, Kotb A. Systematic review of antifungal-induced acute liver failure. Cureus. 2021 Oct;13(10):e18940. doi: 10.7759/cureus.18940
- Fluconazole (diflucan) 150 mg capsule Package Insert (HPRA, Ireland) 2021 [cited Jul Aug 14]. Available from:www.hpra.ie/homepage/medicines/medicines-information/find-a-medicine/results/item?pano=PA0019/044/003&t=DIFLUCAN
- Lewis JH, Zimmerman HJ, Benson GD, et al. Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. Gastroenterology. 1984 Mar;86(3):503–513. doi: 10.1016/S0016-5085(84)80021-9
- Janssen PA, Symoens JE. Hepatic reactions during ketoconazole treatment. Am J Med. 1983 Jan 24;74(1b):80–85. doi: 10.1016/0002-9343(83)90519-3
- Stricker BC, Blok A, Bronkhorst F, et al. Ketoconazole-associated hepatic injury: a clinicopathological study of 55 cases. J Hepatol. 1986;3(3):399–406.
- Griseofulvin 500 mg tablets Package Insert (HPRA, Ireland) 2020 [cited 2023 Aug 14]. Available from: www.hpra.ie/homepage/medicines/medicines-information/find-a-medicine/results/item?pano=PA23148/006/001&t=Griseofulvin%20500%20mg%20film-coated%20tablets
- Cornely OA, Duarte RF, Haider S, et al. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. J Antimicrob Chemother. 2016 Mar;71(3):718–726. doi: 10.1093/jac/dkv380
- Voriconazole (VFEND) 50, 200 mg Tablets Package Insert (European Medicines Agency). 2022 [cited 2023 14 August]. Available from: www.ema.europa.eu/en/documents/product-information/vfend-epar-product-information_en.pdf
- Kao WY, Su CW, Huang YS, et al. Risk of oral antifungal agent-induced liver injury in Taiwanese. Br J Clin Pharmacol. 2014 Jan;77(1):180–189. doi: 10.1111/bcp.12178
- Posaconazole (Posaconazole Accord) 100 mg Tablet Package Insert (European Medicines Agency) 2022 [cited 2023 14 August]. Available from: www.ema.europa.eu/en/medicines/human/EPAR/posaconazole-accord
- Stolmeier DA, Stratman HB, McIntee TJ, et al. Utility of laboratory test result monitoring in patients taking oral terbinafine or Griseofulvin for dermatophyte infections. JAMA Dermatol. 2018 Dec 1;154(12):1409–1416. doi: 10.1001/jamadermatol.2018.3578
- Lo Re V CD 3rd, Lewis JD, Lewis JD, et al. Oral azole antifungal medications and risk of acute liver injury, overall and by chronic liver disease status. Am J Med. 2016 Mar;129(3):283–91.e5. doi: 10.1016/j.amjmed.2015.10.029
- Voriconazole (VFEND) Package Insert (FDA, USA) 2022 [cited 2023 Aug 14]. Available from: www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021266
- Posaconazole (noxafil) 100 mg Tablet Package Insert (FDA, USA) 2022 [cited 2023 Aug 14]. Available from: www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205053
- Ketoconazole (Recorlev) 150 mg tablets Package Insert (FDA, USA) 2021 [cited 2023 Aug 14]. Available from: www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process
- Ketoconazole (Apo-Ketoconazole) 200 mg Tablets Package Insert (HPFB, Canada) 2021 [cited 2023 Aug 14]. Available from: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60554
- Voriconazole (VFEND) 50, 200 mg Tablets Package Insert (HPFB, Canada) 2022 [cited 2023 Aug 14]. Available from: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74170
- Terbinafine (Lamisil) 250 mg Tablet Package Insert (HPFB, Canada) 2022 [cited 2023 14August]. Available from: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13990
- Posaconazole (Apo-Posaconazole) Delayed-Release Tablets 100 mg Package Insert (HPFB, Canada) 2021 [cited 2023 14 August]. Available from: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100104
- Voriconazole (VFEND) 200 mg film-coated tablets Package Insert (MHRA, UK) 2022 [cited 2023 14 August]. Available from: www.medicines.org.uk/emc/product/8408/smpc/print
- Posaconazole (noxafil) 100 mg gastro-resistant tablets Package Insert (MHRA, UK) 2022 [cited 2023 14 August]. Available from: https://www.medicines.org.uk/emc/product/5388/smpc
- Terbinafine (Lamisil) 250 mg Tablet Package Insert (MHRA, UK) 2020 [cited 2023 14 August]. Available from: www.medicines.org.uk/emc/product/1031/smpc/print
- Ketoconazole HRA 200mg tablets Package Insert (MHRA, UK). 2021 [cited 2023 14 August]. Available from: www.medicines.org.uk/emc/product/1767/smpc/print
- Griseofulvin (Gris-Peg) 125, 250 mg Tablets Package Insert (FDA, USA) 2016 [cited 2023 14 August]. Available from: www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process
- Itraconazole (Sporanox) 100 mg Oral Capsules Package Insert (HPFB, Canada) 2022 [cited 2023 14 August]. Available from: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14518
- Itraconazole (Sporanox) 100 mg Capsules Package Insert (MHRA, UK) 2021 [cited 2023 14 August]. Available from: www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SPORANOX-Capsules-pi.pdf
- Fluconazole (Diflucan) 200 mg hard capsules Package Insert (MHRA, UK) 2022 [cited 2023 14 August]. Available from: www.medicines.org.uk/emc/product/5981/smpc/print
- Voriconazole (VFEND) 200 mg tablets Package Insert (RAD-DR, Japan) 2022 [cited 2023 14 August]. Available from: www.rad-ar.or.jp/siori/english/search/result?n=1833
- Posaconazole (noxafil) 100 mg tablets Package Insert (RAD-DR, Japan) 2021 [cited 2023 Aug 14]. Available from: www.rad-ar.or.jp/siori/english/search/result?n=43297
- Terbinafine (Lamisil) 125 mg Tablet Package Insert (RAD-DR, Japan) 2020 [cited 2023 Aug 14]. Available from: www.rad-ar.or.jp/siori/english/search/result?n=43223
- Itraconazole 100 mg tablets Package Insert (RAD-DR, Japan) 2016 [cited 2023 Aug 14]. Available from: www.rad-ar.or.jp/siori/english/search/result?n=33534
- Fluconazole (diflucan) 100 mg Capsules Package Insert (RAD-DR, Japan) 2022 [cited 2023 Aug 14]. Available from: www.rad-ar.or.jp/siori/english/search/result?n=1827
- Tujios SR, Lee WM. Acute liver failure induced by idiosyncratic reaction to drugs: Challenges in diagnosis and therapy. Liver Int. 2018 Jan;38(1):6–14. doi: 10.1111/liv.13535
- Doß S, Potschka H, Doß F, et al. Hepatotoxicity of antimycotics used for invasive fungal infections: In Vitro results. Biomed Res Int. 2017;2017:9658018. doi: 10.1155/2017/9658018
- Rodgers P, Bassler M. Treating onychomycosis. Am Fam Physician. 2001;63(4):663–673.
- Boelaert J, Schurgers M, Matthys E, et al. Itraconazole pharmacokinetics in patients with renal dysfunction. Antimicrob Agents Chemother. 1988 Oct;32(10):1595–1597. doi: 10.1128/AAC.32.10.1595
- Vlahakos DV, Manginas A, Chilidou D, et al. Itraconazole-induced rhabdomyolysis and acute renal failure in a heart transplant recipient treated with simvastatin and cyclosporine. Transplantation. 2002 Jun 27;73(12):1962–1964. doi: 10.1097/00007890-200206270-00022
- Nováková I, Donnelly P, de Witte T, et al. Itraconazole and cyclosporin nephrotoxicity. Lancet. 1987 Oct 17;2(8564):920–921. doi: 10.1016/S0140-6736(87)91412-7
- Stanford Health Care Antimicrobial Dosing Reference Guide 2022 [cited 2023 Aug 15]. Available from: https://med.stanford.edu/content/dam/sm/bugsanddrugs/documents/antimicrobial-dosing-protocols/SHC%20Antimicrobial%20Dosing%20Guide.pdf
- Fluconazole (diflucan) 150 mg capsule Package Insert (HPFB, Canada) 2023 [cited 2023 Aug 14]. Available from: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17789
- Tragiannidis A, Gkampeta A, Vousvouki M, et al. Antifungal agents and the kidney: pharmacokinetics, clinical nephrotoxicity, and interactions. Expert Opin Drug Saf. 2021 Sep;20(9):1061–1074. doi: 10.1080/14740338.2021.1922667
- Duxbury AJ, Oliver RJ, Pemberton MN. Persistent impairment of taste associated with terbinafine. Br Dent J. 2000 Mar 25;188(6):295–296. doi: 10.1038/sj.bdj.4800461a
- Noviasky JA, Sulaiman J. Taste disturbance and hospital admission due to terbinafine. Hosp Pharm. 2004;39(4):351–352. doi: 10.1177/001857870403900411
- Sinha R, Sharma P, Kumar P, et al. Terbinafine-induced taste impairment-report of two cases. J Pak Assoc Dermatol. 2012;22(4):363–365.
- Doty RL, Haxel BR. Objective assessment of terbinafine‐induced taste loss. Laryngoscope. 2005;115(11):2035–2037. doi: 10.1097/01.MLG.0000181462.08683.0C
- Gupta AK, Gonder JR, Shear NH, et al. The development of green vision in association with terbinafine therapy. Arch Dermatol. 1996 Jul;132(7):845–846. doi: 10.1001/archderm.1996.03890310137033
- Belga S, MacDonald C, Kabbani D, et al. When medicine transforms art. Transpl Infect Dis. 2019;21(4):e13130.
- Bayhan GI, Garipardic M, Karaman K, et al. Voriconazole-associated visual disturbances and hallucinations. Cutan Ocul Toxicol. 2016 Mar;35(1):80–82. doi: 10.3109/15569527.2015.1020544
- Baraas RC, Carroll J, Gunther KL, et al. Adaptive optics retinal imaging reveals S-cone dystrophy in tritan color-vision deficiency. J Opt Soc Am A Opt Image Sci Vis. 2007 May;24(5):1438–1447. doi: 10.1364/JOSAA.24.001438
- Purves D, Augustine G, Fitzpatrick D, et al. Viktor Hamburger 1900-2001. Neuroscience. 2001;4(8):777–778.
- Xiong WH, Brown RL, Reed B, et al. Voriconazole, an antifungal triazol that causes visual side effects, is an inhibitor of TRPM1 and TRPM3 channels. Invest Ophthalmol Vis Sci. 2015 Feb 3;56(2):1367–1373. doi: 10.1167/iovs.14-15270
- Kinoshita J, Iwata N, Ohba M, et al. Mechanism of voriconazole-induced transient visual disturbance: reversible dysfunction of retinal ON-bipolar cells in monkeys. Invest Ophthalmol Vis Sci. 2011 Jul 7;52(8):5058–5063. doi: 10.1167/iovs.11-7183
- Martemyanov KA, Sampath AP. The transduction cascade in retinal ON-bipolar cells: signal processing and disease. Annu Rev Vis Sci. 2017 Sep 15;3(1):25–51. doi: 10.1146/annurev-vision-102016-061338
- Morgans CW, Brown RL, Duvoisin RM. TRPM1: the endpoint of the mGlur6 signal transduction cascade in retinal ON-bipolar cells. BioEssays. 2010 Jul;32(7):609–614. doi: 10.1002/bies.200900198
- Kaukonen KM, Olkkola KT, Neuvonen PJ. Itraconazole increases plasma concentrations of quinidine. Clin Pharmacol Ther. 1997 Nov;62(5):510–517. doi: 10.1016/S0009-9236(97)90046-1
- Baxter CG, Marshall A, Roberts M, et al. Peripheral neuropathy in patients on long-term triazole antifungal therapy. J Antimicrob Chemother. 2011 Sep;66(9):2136–2139. doi: 10.1093/jac/dkr233
- Matsumoto K, Ueno K, Yoshimura H, et al. Fluconazole-induced convulsions at serum trough concentrations of approximately 80 microg/mL. Ther Drug Monit. 2000 Oct;22(5):635–636. doi: 10.1097/00007691-200010000-00022
- Cohen PR, Erickson CP, Calame A. Terbinafine-induced lichenoid drug eruption: case report and review of terbinafine-associated cutaneous adverse events. Dermatol Online J. 2020 Jul 15;26(7). doi: 10.5070/D3267049554
- Chaudhary RG, Rathod SP, Jagati A, et al. Oral antifungal therapy: emerging culprits of cutaneous adverse drug reactions. Indian Dermatol Online J. 2019 Mar;10(2):125–130. doi: 10.4103/idoj.IDOJ_353_18
- Grayson ML, Cosgrove SE, Crowe S, et al. Kucers’ the use of antibiotics: a clinical review of antibacterial, antifungal, Antiparasitic, and antiviral drugs, -three volume set. Florida, United States: CRC Press; 2017.
- Castellsague J, García-Rodríguez L-A, Duque A, et al. Risk of serious skin disorders among users of oral antifungals: a population-based study. BMC Dermatol. 2002;2(1):1–6.
- Itraconazole (Sporanox) 100 mg Capsules Package Insert (HPRA, Ireland) 2023 [cited 2023 Aug 14]. Available from: https://www.hpra.ie/homepage/medicines/medicines-information/find-a-medicine/results/item?pano=PPA0465/400/001&t=Sporanox%20100%20mg%20Capsules
- Ricardo JW, Lipner SR. Safety of current therapies for onychomycosis. Expert Opin Drug Saf. 2020;19(11):1395–1408. doi: 10.1080/14740338.2020.1829592
- Andersson NW, Thomsen SF, Andersen JT. Evaluation of association between oral and topical terbinafine use in pregnancy and risk of major malformations and spontaneous abortion. JAMA Dermatol. 2020;156(4):375–383. doi: 10.1001/jamadermatol.2020.0142
- Safety communication: use of long-term, high-dose fluconazole (difucan) during pregnancy may be associated with birth defects in infants (FDA, USA) 2011 [cited 2023 Aug 14]. Available from: www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communicationuse-long-term-high-dose-diflucan-fluconazole-during-pregnancy-may-be
- Fluconazole Pregnancy and Breastfeeding Warnings (Drugs.com). 2023. cited 2023 Aug 18. Available from: https://www.drugs.com/pregnancy/fluconazole.html
- Bérard A, Sheehy O, Zhao J-P, et al. Associations between low-and high-dose oral fluconazole and pregnancy outcomes: 3 nested case–control studies. CMAJ. 2019;191(7):E179–E187.
- Zhu Y, Bateman BT, Gray KJ, et al. Oral fluconazole use in the first trimester and risk of congenital malformations: population based cohort study. BMJ. 2020;369.
- Pursley TJ, Blomquist IK, Abraham J, et al. Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis. 1996;22(2):336–340.
- Scarlattilaan D What is diflucan? Why was diflucan reviewed? What are the conclusions of the CHMP? 2012 [cited 2023 Aug 14]. Available from: www.ema.europa.eu/en/medicines/human/referrals/diflucan
- Darkes MJ, Scott LJ, Goa KL. Terbinafine: a review of its use in onychomycosis in adults. Am J Clin Dermatol. 2003;4(1):39–65. doi: 10.2165/00128071-200304010-00005
- Bueno JG, Martinez C, Zapata B, et al. In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis. Clin Exp Dermatol. 2010 Aug;35(6):658–663. doi: 10.1111/j.1365-2230.2009.03698.x
- Sacheli R, Hayette MP. Antifungal resistance in dermatophytes: genetic considerations, clinical presentations and alternative therapies. J Fungi (Basel). 2021 Nov 18;7(11):983. doi: 10.3390/jof7110983
- Leber R, Fuchsbichler S, Klobucníková V, et al. Molecular mechanism of terbinafine resistance in Saccharomyces cerevisiae. Antimicrob Agents Chemother. 2003;47(12):3890–3900.
- Souza AC, Ge W, Wiederhold NP, et al. hapE and hmg1 mutations are drivers of cyp51A-independent pan-triazole resistance in an Aspergillus fumigatus clinical isolate. Microbiol Spectr. 2023;11(3):e05188–22.
- Gupta AK, Talukder M, Carviel JL, et al. Combatting antifungal resistance: paradigm shift in the diagnosis and management of onychomycosis and dermatomycosis. J Eur Acad Dermatol Venereol. 2023 May 21;37(9):1706–1717. doi: 10.1111/jdv.19217
- Alastruey-Izquierdo A, Cuenca-Estrella M. EUCAST and CLSI: how to assess in vitro susceptibility and clinical resistance. Curr Fungal Infect Rep. 2012;6(3):229–234. doi: 10.1007/s12281-012-0100-3
- Espinel-Ingroff A, Barchiesi F, Cuenca-Estrella M, et al. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol. 2005 Aug;43(8):3884–3889. doi: 10.1128/JCM.43.8.3884-3889.2005
- Bar-Yosef H, Vivanco Gonzalez N, Ben-Aroya S, et al. Chemical inhibitors of Candida albicans hyphal morphogenesis target endocytosis. Sci Rep. 2017;7(1):5692.